The DEA was expected to move forward with its plans this week to remove cannabis as a Schedule 1 drug, where it currently sits alongside heroin and LSD, but new reports suggest the proposal has stalled.
"Cannabis is just getting started and there's going to be a lot of companies getting ready to take advantage of this massive growth cycle, government reform, news states, opening new opportunities and one day, interstate commerce." That's according to Benzinga's cannabis stock expert, Michael Berger, who is on a mission to uncover the most promising marijuana stocks poised for growth, even in a dull market.
Zig-Zag rolling paper manufacturer Turning Point Brands, Inc. (NYSE:TPB) reported financial results Thursday for the first quarter ended March 31, 2024…
Colombian cannabis company Sannabis makes U.S. debut with essential oil shipment, navigating regulatory hurdles while exploring industry potential and partnerships